Skip to main content
main-content

14-12-2019 | Breast cancer | Video

SABCS 2019 | Residual cancer burden after neoadjuvant therapy predicts breast cancer relapse risk

W Fraser Symmans takes us through their patient-level pooled analysis identifying residual cancer burden as a predictive factor for recurrence across all breast cancer subtypes, and its subsequent potential to inform treatment choice (6:49).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits